The Los Angeles Post
U.S. World Business Lifestyle
Today: March 26, 2025
Today: March 26, 2025
Leroy Leo

Leroy Leo

Staff Writer

Latest From Leroy Leo

Business|Health|News|US

Explainer-Why are Kaiser Permanente healthcare workers on strike?

About 75,000 medical workers from Kaiser Permanente facilities went on a planned three-day strike on Wednesday, putting pressure on one of the leading not-

Explainer-Why are Kaiser Permanente healthcare workers on strike?
Business|Finance|Health

Abbott says market overestimating sales hit from new diabetes drugs

Abbott Laboratories said the market was overestimating the hit to sales of its glucose monitoring products from growing popularity of new diabetes drugs,

Abbott says market overestimating sales hit from new diabetes drugs
Business|Finance|Health|US

AbbVie takes $2.1 billion charge on cancer drug ahead of US price negotiation

AbbVie, girding for government price negotiations on its big-selling cancer drug Imbruvica, on Friday disclosed a $2.1 billion charge related to an expected drop in revenue

AbbVie takes $2.1 billion charge on cancer drug ahead of US price negotiation
Business|Health|US

Pharmacy staff from CVS, Walgreens stores in US start 3-day walkout

Some employees at CVS Health Corp and Walgreens Boots Alliance's U.S. pharmacies launched a three-day walkout starting Monday to get the companies to improve working

Pharmacy staff from CVS, Walgreens stores in US start 3-day walkout
Health|News|US

US Consumer group seeks stronger warnings on Botox, similar treatments

Consumer advocacy group Public Citizen on Tuesday filed a petition with the U.S.

US Consumer group seeks stronger warnings on Botox, similar treatments
Business|Finance|Stock Markets

Pfizer shares sink after it resets 2024 COVID expectations

Pfizer on Wednesday forecast 2024 sales that could be as much as $5 billion below Wall Street expectations, a move top executives said provided a more

Pfizer shares sink after it resets 2024 COVID expectations
Business|Finance|Health

Moderna reports surprise profit, sets out road map for RSV vaccine

Moderna on Thursday reported a surprise fourth-quarter profit helped by cost cutting and some deferred payments, and the vaccine maker set out a

Moderna reports surprise profit, sets out road map for RSV vaccine
Business|Health|US

Drugmaker AbbVie expects Humira volume erosion to worsen

AbbVie expects a drop in sales volumes of its blockbuster arthritis drug Humira to deepen after recent changes by U.S. pharmacy benefit managers and as

Drugmaker AbbVie expects Humira volume erosion to worsen
Business|Finance

CVS cuts annual profit forecast and flags challenges in 2025, shares fall 18%

CVS Health Corp slashed its annual profit forecast on Wednesday and flagged challenges for next year's health insurance plans for older adults, and its

CVS cuts annual profit forecast and flags challenges in 2025, shares fall 18%
Health|Science

U.S. FDA advisers back approval for Guardant's blood-based cancer test (May 23)

(This May 23 story has been corrected to say Shield is meant for CRC screening, not diagnosis, in paragraph 4, and fix a typo in paragraph 7.)

U.S. FDA advisers back approval for Guardant's blood-based cancer test (May 23)
US

US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump

The U.S.

US FDA approves expanded use of Sarepta's Duchenne gene therapy; shares jump
Business|News|Science

Musk's Neuralink says tiny wires of brain chip in first patient now stable

The tiny wires of Neuralink's brain chip implant used in the first participant in a trial run by Elon Musk's company have become "more or less very stable", a

Musk's Neuralink says tiny wires of brain chip in first patient now stable
Business|Finance|Health

Abbott plans marketing push for glucose monitors beyond diabetes

Abbott Laboratories will use a mix of TV advertisements and guerilla marketing as well as seek to personalize health data to tap people without diabetes for

Abbott plans marketing push for glucose monitors beyond diabetes
Business|Finance|Health

CVS Health expects medical costs to remain high through the year

CVS Health said on Wednesday that high demand for medical care among older adults hit second-quarter results, a trend that continued into July,

CVS Health expects medical costs to remain high through the year
Business|Health

UnitedHealth tech unit's rivals say new, post-hack customers are staying

Smaller rivals to UnitedHealth's tech unit Change Healthcare say they are signing longer-term contracts with hospitals and other customers who had temporarily

UnitedHealth tech unit's rivals say new, post-hack customers are staying
Business|Health|US

CVS names Joyner as CEO under investor pressure, withdraws profit forecast

CVS Health on Friday replaced CEO Karen Lynch with David Joyner, a CVS veteran who retired before returning to the company last year, after investors including

CVS names Joyner as CEO under investor pressure, withdraws profit forecast
Business|Finance|Health|US

Merck sees Gardasil China woes carrying into 2025

Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories

Merck sees Gardasil China woes carrying into 2025
Business|Finance|Health|US

Merck sees Gardasil China woes carrying into 2025

Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories

Merck sees Gardasil China woes carrying into 2025
Asia|Business|Finance|Health

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova

Merck has licensed an early-stage cancer drug from a China-based biotech in an up to $3.3 billion deal, two months after a similar therapy from Summit Therapeutics outperformed

Merck signs up to $3.3 billion cancer drug deal with China-based LaNova
Business|Finance|Stock Markets|US

Walgreens in talks to be taken private by Sycamore Partners, source says

Walgreens Boots Alliance is in talks to sell itself to private equity firm Sycamore Partners, according to a person familiar with the matter, the latest attempt

Walgreens in talks to be taken private by Sycamore Partners, source says

Follow